XNK Therapeutics AB, a Sweden-based clinical stage immunotherapy company that is focused on bringing new and more effective treatments to cancer patients, announced on Monday that Johan Liwing, CEO, will make a presentation at the DNB Nordic Healthcare Conference in Oslo, Norway, on 14 December at 10:15am CET.
This presentation will be followed by a short Q&A session, moderated by a DNB analyst.
The company is developing autologous NK cell-based cell therapy with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumour indications. Its most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001